Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 49.12% is 27% below its 5-year average of 67.19%, near the low end of its 5-year range (45.87%–80.64%).
1.34% above its 12-month average of 48.47%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 51.06%.
GROSS MARGIN
49.12%
GROSS MARGIN AVG TTM
48.47%
GROSS MARGIN AVG 3Y
61.42%
GROSS MARGIN AVG 5Y
67.19%
GROSS MARGIN AVG 10Y
76.11%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.34%
CURRENT VS 3Y AVG
-20.03%
CURRENT VS 5Y AVG
-26.90%
CURRENT VS 10Y AVG
-35.46%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+18.70%
vs the sector median at left
Neuronetics, Inc.
Market Cap
$153.79M
Gross Margin
49.12%
TTM Avg
48.47%
3Y Avg
61.42%
5Y Avg
67.19%
Market Cap
$153.58M
Gross Margin
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$151.01M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
Market Cap
$149.36M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
1.51%
Market Cap
$148.73M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
-394.61%
5Y Avg
-639.25%
Market Cap
$148.64M
Gross Margin
-227.62%
TTM Avg
-63.81%
3Y Avg
-25.20%
5Y Avg
-26.93%
Market Cap
$159.14M
Gross Margin
63.55%
TTM Avg
56.95%
3Y Avg
54.72%
5Y Avg
65.55%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $153.79M | 49.12% | 48.47% | 61.42% | 67.19% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | 0.00% | 0.00% | 0.00% |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | 48.89% | 46.84% | 43.63% | 44.77% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | 0.00% | 0.00% | 0.00% | -29.98% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | 0.00% | 0.00% | 0.00% | 1.51% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | 100.00% | 100.00% | -394.61% | -639.25% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -227.62% | -63.81% | -25.20% | -26.93% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | 63.55% | 56.95% | 54.72% | 65.55% |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | 85.91% | 84.21% | 85.09% | 82.87% |
Gross Margin
49.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 51.06% |
| 2026-03-31 | 46.89% |
| 2025-12-31 | 51.95% |
| 2025-09-30 | 45.87% |
| 2025-06-30 | 46.60% |
| 2025-03-31 | 49.22% |
| 2024-12-31 | 66.21% |
| 2024-09-30 | 75.56% |
| 2024-06-30 | 74.04% |
| 2024-03-31 | 75.14% |
| 2023-12-31 | 77.64% |
| 2023-09-30 | 65.78% |
| 2023-06-30 | 72.54% |
| 2023-03-31 | 73.33% |
| 2022-12-31 | 75.88% |
| 2022-09-30 | 78.36% |
| 2022-06-30 | 75.26% |
| 2022-03-31 | 75.42% |
| 2021-12-31 | 76.45% |
| 2021-09-30 | 77.22% |
| 2021-06-30 | 80.64% |
| 2021-03-31 | 81.93% |
| 2020-12-31 | 75.85% |
| 2020-09-30 | 78.66% |
| 2020-06-30 | 76.15% |
| 2020-03-31 | 75.51% |
| 2019-12-31 | 75.69% |
| 2019-09-30 | 73.80% |
| 2019-06-30 | 74.83% |
| 2019-03-31 | 77.95% |
| 2018-12-31 | 76.26% |
| 2018-09-30 | 77.91% |
| 2018-06-30 | 75.51% |
| 2018-03-31 | 75.80% |
| 2017-12-31 | 75.58% |
| 2017-09-30 | 74.87% |
| 2017-06-30 | 75.74% |
| 2017-03-31 | 79.56% |
